Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.66 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.59 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | UBE2N | P61088 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1970415 | 0.92 | S1PR1 (0.60) | S1PR1S1PR3S1PR4S1PR5KDM4E | |
| SCHEMBL1968240 | 0.91 | S1PR1 (0.67) | S1PR1S1PR3S1PR4S1PR5KDM4E | |
| SCHEMBL1489125 | 0.90 | S1PR1 (0.60) | S1PR1S1PR3S1PR4S1PR5KDM4E | |
| SCHEMBL12386204 | 0.89 | S1PR1 (0.59) | S1PR1S1PR3S1PR4S1PR5KDM4E | |
| SCHEMBL1966814 | 0.89 | S1PR1 (0.63) | S1PR1S1PR3S1PR4S1PR5KDM4E | |
| SCHEMBL1488870 | 0.89 | S1PR1 (0.63) | S1PR1S1PR3S1PR4S1PR5KDM4E | |
| SCHEMBL1489021 | 0.89 | S1PR1 (0.61) | S1PR1S1PR3S1PR4S1PR5KDM4E | |
| SCHEMBL12779879 | 0.88 | S1PR1 (0.62) | S1PR1S1PR3S1PR4S1PR5KDM4E | |
| SCHEMBL12830873 | 0.87 | S1PR1 (0.69) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL1488988 | 0.87 | S1PR1 (0.59) | S1PR1S1PR3S1PR4S1PR5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110200557-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | ALMIRALL, S.A. (ES) | 2011-08-18 | — | — | US | claimed |
| EP-2334670-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | Almirall S.A. (ES) | 2011-06-22 | — | — | EP | claimed |
| WO-2010043377-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | ALMIRALL, S.A. (ES) | 2010-04-22 | — | — | WO | claimed |
| EP-2177521-A1 | New 2-Amidothiadiazole Derivatives | Almirall, S.A. (ES) | 2010-04-21 | — | — | EP | claimed |
| US-20110200557-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | ALMIRALL, S.A. (ES) | 2011-08-18 | — | — | US | disclosed |
| US-20110200557-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | ALMIRALL, S.A. (ES) | 2011-08-18 | — | — | US | disclosed |
| US-20110200557-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | ALMIRALL, S.A. (ES) | 2011-08-18 | — | — | US | disclosed |
| EP-2334670-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | Almirall S.A. (ES) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010043377-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | ALMIRALL, S.A. (ES) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010043377-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | ALMIRALL, S.A. (ES) | 2010-04-22 | — | — | WO | disclosed |
| EP-2177521-A1 | New 2-Amidothiadiazole Derivatives | Almirall, S.A. (ES) | 2010-04-21 | — | — | EP | disclosed |
| EP-2177521-A1 | New 2-Amidothiadiazole Derivatives | Almirall, S.A. (ES) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110200557-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | S1PR2, S1PR3, S1PR1 | S1PR1 3/4885S1PR3 2/4885S1PR4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.